info@cytospector.com
Cytospector
  • Home
  • Expertise
  • High-content assays
    • Standardized phenotypic assay
    • Alzheimer´s disease assay
    • Schizophrenia assay
  • Assay development
  • About us
  • Contact
  • Home
  • Expertise
  • High-content assays
    • Standardized phenotypic assay
    • Alzheimer´s disease assay
    • Schizophrenia assay
  • Assay development
  • About us
  • Contact

Schizophrenia assay

Cytospector’s assay for schizophrenia evaluates the effect of selected compounds or genes on disease-associated pathways. This assay can be used to identify novel therapeutics or targets for schizophrenia.

MicroRNA-137 (MIR137) has been implicated in the development of schizophrenia by GWAS and functional studies. MIR137 regulates several pathways that are involved in the etiology of this disorder. By genetically targeting MIR137, we induce a synaptic phenotype that mimics schizophrenia-associated pathology in humans. Our schizophrenia assay evaluates the potency of selected experimental manipulations to rescue this synaptic phenotype.

STANDARD PHENOTYPIC ASSAY

based on a variety of cellular and synaptic parameters

Read More

ALZHEIMER´S DISEASE ASSAY

For compound of genetic screens

Read More

SCHIZOPHRENIA ASSAY

For compound or genetics screens

Read More

CYTOSPECTOR

  • Home
  • Expertise
  • High-content assays
  • Standardized phenotypic assay
  • Alzheimer´s disease assay
  • Assay development
  • About us
  • Contact

CONTACT

Cytospector
PO Box 71033
1008 BA Amsterdam
The Netherlands

info@cytospector.com

© Copyright 2015 •Cytospector •